- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Mark Fendrick Highlights VBID Elements in the Inflation Reduction Act
Elements inspired by the principles of value-based insurance design (VBID) were incorporated into the recently signed Inflation Reduction Act, which could help reduce costs of care for patients, according to A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Elements inspired by the principles of value-based insurance design (VBID) were incorporated into the recently signed Inflation Reduction Act (IRA), which could help reduce costs of care for patients, according to A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Transcript
How is the IRA implementing some VBID elements to reduce out-of-pocket costs for essential medical services?
We were very excited to see that the Inflation Reduction Act of 2022 includes several value-based insurance design, or VBID, related elements. Notably, first, it caps Medicare patients’ out-of-pocket costs at $2000 per year, with an option to break that amount into affordable monthly payments. Second, it covers adult vaccines recommended by the Advisory Committee on Immunization Practices at the CDC, under Medicare Part D without cost sharing. Third is amendment of the Internal Revenue Service code to create a safe harbor allowing health savings account qualified health plans to cover insulin prior to meeting the plan deductible, and most notably and covered widespread by the media, the cap on Medicare patients’ out-of-pocket costs for insulin at $35 per month.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
